Oral News and Research

RSS

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C).

29 Jun 2015

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Egalet Corporation today announced positive results from a Category 3 intranasal human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

29 Jun 2015

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments.

29 Jun 2015

NYU physician suggests changes for a healthier home

(Family Features) Dirt. Grime. Bacteria. Airborne allergens. As hard as you try to keep your home clean, these types of yucky things are an everyday reality. Taking the necessary steps to create a healthy home can not only give you peace of mind, but also help keep your family healthier.

27 Jun 2015

Alabama scientists show how phytochemical in magnolia works against head and neck cancers

Magnolias are prized for their large, colorful, fragrant flowers. Does the attractive, showy tree also harbor a potent cancer fighter?

26 Jun 2015

Long-acting injectable antipsychotic medication benefits people with schizophrenia

Schizophrenia, which affects 2 million to 3 million people in the U.S., causes hallucinations, delusions and disorganization. Left untreated, the disease can cause a significant loss in quality of life, including unemployment and estrangement from loved ones. But many people with schizophrenia can control the disorder and live without symptoms for several years if they consistently take prescribed antipsychotic medication, typically a daily pill.

25 Jun 2015

Uninterrupted NOAC treatment during catheter ablation of atrial fibrillation is safe, shows research

Uninterrupted treatment with novel oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) is safe, reveals research presented today at EHRA EUROPACE - CARDIOSTIM 2015 by Dr Carsten Wunderlich, senior consultant in the Department of Invasive Electrophysiology, Heart Centre Dresden, Germany.

25 Jun 2015

Rising number of malaria deaths likely to exceed total number of Ebola deaths

Around 74000 fewer malaria cases than expected were seen at health facilities in Guinea in 2014 compared with pre-Ebola years, new research published in The Lancet Infectious Diseases journal has found.

25 Jun 2015

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.

24 Jun 2015

10-week reading intervention improves brain activity in autistic children

Ten weeks of intensive reading intervention for children with autism spectrum disorder was enough to strengthen the activity of loosely connected areas of their brains that work together to comprehend reading, University of Alabama at Birmingham researchers have found.

24 Jun 2015

Study analyzes effects of inhaled cannabis on driving performance

A new study conducted at the University of Iowa's National Advanced Driving Simulator has found drivers who use alcohol and marijuana together weave more on a virtual roadway than drivers who use either substance independently.

24 Jun 2015

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen.

24 Jun 2015

Stress during pregnancy affects babies' brain development

Stress during the first trimester of pregnancy alters the population of microbes living in a mother's vagina. Those changes are passed on to newborns during birth and are associated with differences in their gut microbiome as well as their brain development, according to a new study by University of Pennsylvania researchers.

23 Jun 2015

Celimmune to provide oral presentation on AMG 714 antibody at 16th International Coeliac Disease Symposium

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that Dr. Francisco Leon, CEO and Chief Medical Officer, will provide an oral presentation on an abstract related to the company's lead product candidate, AMG 714, at the 16th International Coeliac Disease Symposium, June 24, 2015, in Prague, Czech Republic.

22 Jun 2015

Analysis of ancient DNA shows that Kennewick Man more closely related to Native Americans

DNA from the 8,500-year-old skeleton of an adult man found in 1996, in Washington, is more closely related to Native American populations than to any other population in the world, according to an international collaborative study conducted by scientists at the University of Copenhagen and the Stanford University School of Medicine.

19 Jun 2015

Scientists reveal new combination method that efficiently destroys cancer cells

Scientists at the Institut Pasteur and Inserm have successfully increased the infiltration of immune cells into tumors, thus inducing the immune system to block tumor growth. In an article published in Nature Immunology, the scientists show that, in combination with existing immunotherapies, this process efficiently destroys cancer cells.

18 Jun 2015

Exploring potential alternatives to needle injections

Needle injections have been around since 1657 and remain a key delivery method for many drugs, including vaccines that have prevented countless illnesses. But for patients that require daily pricks or for people in remote locations, the syringe model has major drawbacks. An article in Chemical & Engineering News looks at potential alternatives, their successes and their roadblocks.

18 Jun 2015

University of Bristol researchers develop new technology to increase protection against bacterial infection

A new technology which could increase protection against antibacterial and antifungal infection for weeks, months or years has been developed by researchers at the University of Bristol.

18 Jun 2015

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022" the Heparin Market Europe was valued at USD 2,004.5 million in 2013 and is estimated to reach USD 3,148.0 million by 2022 growing with a CAGR of 5.2% from 2014 to 2022.

17 Jun 2015

RPCI receives NCI grant to continue research program on photodynamic therapy for head and neck cancers

Roswell Park Cancer Institute has received continuation of a prestigious program project grant from the National Cancer Institute for research through the Roswell Park Photodynamic Therapy Center.

17 Jun 2015

Oral News and Research

Synthetic Biologics announces initiation of SYN-010 Phase 2 clinical trial for treatment of IBS-C

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

NYU physician suggests changes for a healthier home

Alabama scientists show how phytochemical in magnolia works against head and neck cancers

Long-acting injectable antipsychotic medication benefits people with schizophrenia

Uninterrupted NOAC treatment during catheter ablation of atrial fibrillation is safe, shows research

Rising number of malaria deaths likely to exceed total number of Ebola deaths

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

10-week reading intervention improves brain activity in autistic children

Study analyzes effects of inhaled cannabis on driving performance

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Stress during pregnancy affects babies' brain development

Celimmune to provide oral presentation on AMG 714 antibody at 16th International Coeliac Disease Symposium

Analysis of ancient DNA shows that Kennewick Man more closely related to Native Americans

Scientists reveal new combination method that efficiently destroys cancer cells

Exploring potential alternatives to needle injections

University of Bristol researchers develop new technology to increase protection against bacterial infection

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

RPCI receives NCI grant to continue research program on photodynamic therapy for head and neck cancers

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News